KeyCorp Forecasts Alpha Teknova FY2027 Earnings

Key Points

• KeyCorp forecasts Alpha Teknova will lose $0.20 per share in FY2027, a smaller loss than the current consensus estimate of $0.26 per share.
• In its latest quarter, Alpha Teknova reported a loss of $0.06 per share, beating estimates by $0.01, while revenue of $12.7 million exceeded the $11.71 million consensus.
• Analyst views are mostly positive: MarketBeat reports a “Moderate Buy” consensus and an $8.75 average price target, though one analyst rates the stock a Sell.

Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) - Analysts at KeyCorp issued their FY2027 earnings estimates for shares of Alpha Teknova in a research report issued on Wednesday, November 4th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Alpha Teknova's current full-year earnings is ($0.26) per share.

Several other research analysts have also issued reports on TKNO. TD Cowen raised their target price on Alpha Teknova from $7.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alpha Teknova in a report on Wednesday, November 4th. Roth Capital assumed coverage on Alpha Teknova in a research report on Wednesday, August 5th. They issued a "buy" rating and a $7.00 price target on the stock. BTIG Research raised Alpha Teknova from a "neutral" rating to a "buy" rating and set a $8.00 price target for the company in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised Alpha Teknova from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

Alpha Teknova Stock Performance

Shares of Alpha Teknova stock opened at $8.30 on Friday. The company has a quick ratio of 3.48, a current ratio of 3.56 and a debt-to-equity ratio of 0.22. Alpha Teknova has a twelve month low of $1.91 and a twelve month high of $9.48. The stock has a market cap of $522.07 million, a price-to-earnings ratio of -28.62 and a beta of 0.96. The company's fifty day moving average is $7.83 and its 200 day moving average is $5.09.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $11.71 million. Alpha Teknova had a negative net margin of 34.76% and a negative return on equity of 24.95%.

Institutional Trading of Alpha Teknova

Several hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new stake in Alpha Teknova in the second quarter worth $115,000. Bank of America Corp DE bought a new stake in Alpha Teknova in the second quarter valued at $1,453,000. Ieq Capital LLC bought a new stake in Alpha Teknova in the second quarter valued at $62,000. BlackRock Inc. acquired a new position in shares of Alpha Teknova during the second quarter valued at about $4,997,000. Finally, Deutsche Bank AG acquired a new position in shares of Alpha Teknova during the second quarter valued at about $62,000. Institutional investors own 13.81% of the company's stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc. develops and manufactures reagents used in life science research and the development and production of biopharmaceuticals and diagnostic products. Its offerings include cell culture media, buffers, molecular biology reagents, proteins and other laboratory materials. The company provides both catalog products and custom reagent development and manufacturing services. Its customers include biotechnology and pharmaceutical companies, diagnostic developers, academic institutions and research laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.